Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Debt to Equity (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Debt to Equity for 4 consecutive years, with -$0.48 as the latest value for Q4 2025.

  • On a quarterly basis, Debt to Equity rose 39.92% to -$0.48 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.48, a 39.92% increase, with the full-year FY2025 number at -$0.48, up 39.92% from a year prior.
  • Debt to Equity was -$0.48 for Q4 2025 at Phathom Pharmaceuticals, up from -$0.49 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $5.56 in Q2 2023 to a low of -$13.2 in Q2 2022.
  • A 4-year average of -$1.51 and a median of -$0.87 in 2024 define the central range for Debt to Equity.
  • Biggest YoY gain for Debt to Equity was 142.09% in 2023; the steepest drop was 144.76% in 2023.
  • Phathom Pharmaceuticals' Debt to Equity stood at -$1.27 in 2022, then tumbled by 48.78% to -$1.89 in 2023, then skyrocketed by 58.08% to -$0.79 in 2024, then soared by 39.92% to -$0.48 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Debt to Equity are -$0.48 (Q4 2025), -$0.49 (Q3 2025), and -$0.51 (Q2 2025).